Clinical types of checkpoint inhibitor-related pneumonitis in lung cancer patients: a multicenter experience

Lin, Xinqing1,2; Deng, Haiyi1; Chen, Likun3,4,5; Wu, Di6; Chen, Xiaobo1; Yang, Yilin1; Chen, Tao1; Xie, Xiaohong1; Xie, Zhanhong1; Liu, Ming1; Ouyang, Ming1; Qin, Yinyin1; Li, Shiyue1; Zhong, Nanshan1; Gregg, Jeffrey P.7; Horita, Nobuyuki8; Song, Yong2,9; Zhou, Chengzhi1

2021

10.21037/tlcr-20-1258

Translational Lung Cancer Research   影响因子和分区

2218-6751

2226-4477

["Background: Checkpoint inhibitor-related pneumonitis (CIP) is not well classified according to clinical factors. We propose different clinical sub-types of CIP based on clinical factors and investigated the corresponding clinical features, treatments, and outcomes.","Methods: We conducted a multicenter retrospective study of patients with lung cancer (including non-small cell lung cancer and small cell lung cancer) who developed CIP. The clinical characteristics, radiologic features, treatments, and outcomes of CIP were analyzed.","Results: A total of 55 patients developed CIP and were classified into 3 groups as follows: 21 in the pure type (PT) group, 14 in the induced type (IT) group, and 20 in the mixed type (MT) group. The incidence of severe (grade 3-5) pneumonitis was significantly higher in the IT group than in the PT and MT groups (71.4% vs. 14.3% vs. 50.0%, P=0.002). Antiviral therapy was significantly more frequent in the IT group than in the PT and MT groups. Antibiotic therapy was administered in 23.8%, 71.4%, and 80.0% of patients with the PT, IT, and MT, respectively. The improvement time in the PT group was longer than that in the IT and MT groups (0.9 vs. 0.5 vs. 0.3 months, P=0.028). Patients with the PT had a better tumor response to immune checkpoint inhibitors (ICIs) than those with the other 2 types [overall response rate (ORR), 78% vs. 31% vs. 44%, P=0.027].","Conclusions: The clinical classification of CIP may favor strategies for treatments and predict the tumor response to ICIs."]

Immune checkpoint inhibitor (ICI) immune-related adverse events checkpoint inhibitor-related pneumonitis (CIP) lung cancer clinical types

SCI

英语

其他

Guangdong High-Level University Clinical Cultivation Project[2017-21020] ; Guangzhou Science and Technology Program key projects[202008010006] ; Wu Jieping Medical Foundation[20201101]

Oncology ; Respiratory System

Oncology ; Respiratory System

WOS:000616118200017

AME PUBL CO

Web of Science

1.Guangzhou Med Univ, Natl Clin Res Ctr Resp Dis, Guangzhou Inst Resp Hlth, State Key Lab Resp Dis,Affiliated Hosp 1, Guangzhou, Peoples R China
2.Southern Med Univ, Sch Clin Med 1, Guangzhou, Peoples R China
3.Sun Yat Sen Univ, Canc Ctr, Dept Med Oncol, Guangzhou, Peoples R China
4.State Key Lab Oncol South China, Guangzhou, Peoples R China
5.Collaborat Innovat Ctr Canc Med, Guangzhou, Peoples R China
6.Southern Univ Sci & Technol, Jinan Univ, Clin Med Coll 2, Affiliated Hosp 1,Shenzhen Peoples Hosp, Shenzhen, Guangdong, Peoples R China
7.Univ Calif Davis, Med Ctr, Dept Pathol & Lab Med, Sacramento, CA 95817 USA
8.Yokohama City Univ, Grad Sch Med, Dept Pulmonol, Yokohama, Kanagawa, Japan
9.Jinling Hosp, Dept Resp & Crit Care Med, Nanjing, Peoples R China

Lin, Xinqing,Deng, Haiyi,Chen, Likun,et al. Clinical types of checkpoint inhibitor-related pneumonitis in lung cancer patients: a multicenter experience[J]. Translational Lung Cancer Research,2021,10(1).

Lin, Xinqing.,Deng, Haiyi.,Chen, Likun.,Wu, Di.,Chen, Xiaobo.,...&Zhou, Chengzhi.(2021).Clinical types of checkpoint inhibitor-related pneumonitis in lung cancer patients: a multicenter experience.Translational Lung Cancer Research,10(1).

Lin, Xinqing,et al."Clinical types of checkpoint inhibitor-related pneumonitis in lung cancer patients: a multicenter experience".Translational Lung Cancer Research 10.1(2021).